Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

SHE:300497 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	632.74	695.35	729.37	978.03	1,272	1,585
Trading Asset Securities	1.98	2.19	2.19	49.74	150.76	106.68
Cash & Short-Term Investments	634.71	697.54	731.56	1,028	1,423	1,692
Cash Growth	-6.23%	-4.65%	-28.82%	-27.79%	-15.88%	105.98%
Accounts Receivable	420.04	498.16	572.92	552.49	376.21	314.38
Other Receivables	44.69	53.85	128.31	78.21	80.01	57.44
Receivables	464.73	552.01	701.23	630.71	456.22	371.82
Inventory	406.04	421.05	434.68	553.69	416.15	287.98
Other Current Assets	18.88	10.42	9.97	17.11	15.97	14.98
Total Current Assets	1,524	1,681	1,877	2,229	2,312	2,367
Property, Plant & Equipment	2,281	2,267	2,331	2,201	1,857	1,199
Long-Term Investments	251.19	255.9	271.27	271.42	133.02	153.78
Goodwill	-	-	-	1.15	2.22	2.22
Other Intangible Assets	289.31	235	241.07	249.71	256.32	246.28
Long-Term Deferred Tax Assets	31.1	37.26	29.37	28.49	27.54	9.29
Long-Term Deferred Charges	-	-	-	-	-	2.2
Other Long-Term Assets	60.55	60.95	69.13	78.79	90.82	66.71
Total Assets	4,438	4,537	4,819	5,060	4,678	4,046
Accounts Payable	384.37	603.37	581.93	656.67	517.05	418.6
Accrued Expenses	15.82	44.05	44.52	42.4	51.97	37.75
Short-Term Debt	631.39	556.4	549.83	366.74	615.18	377.38
Current Portion of Long-Term Debt	260.9	311.78	78.78	7.96	33.5	-
Current Income Taxes Payable	10.69	0.05	0.82	8.71	13.89	42.11
Current Unearned Revenue	3.29	2.72	3.4	1.42	1.82	2.81
Other Current Liabilities	25.25	25.46	26.32	174.96	126.56	6.25
Total Current Liabilities	1,332	1,544	1,286	1,259	1,360	884.9
Long-Term Debt	829.47	736.48	998.26	1,043	353	65
Long-Term Unearned Revenue	106.89	77.67	62.39	62.03	50.3	43.73
Long-Term Deferred Tax Liabilities	1.89	1.96	2.05	6.27	3.92	4.3
Total Liabilities	2,270	2,360	2,348	2,370	1,767	997.93
Common Stock	538.65	550	550	550	550	550
Additional Paid-In Capital	1,247	1,381	1,414	1,408	1,406	1,465
Retained Earnings	346.03	408.78	680.88	881.68	1,023	1,084
Treasury Stock	-	-174.86	-174.86	-174.86	-105.11	-100.02
Comprehensive Income & Other	16.82	15.45	14.3	16.89	6.08	8.34
Total Common Equity	2,149	2,180	2,485	2,681	2,880	3,007
Minority Interest	19.39	-3.54	-14.06	8.4	31.1	40.39
Shareholders' Equity	2,168	2,177	2,471	2,690	2,911	3,048
Total Liabilities & Equity	4,438	4,537	4,819	5,060	4,678	4,046
Total Debt	1,722	1,605	1,627	1,418	1,002	442.38
Net Cash (Debt)	-1,087	-907.13	-895.31	-389.97	421.54	1,249
Net Cash Growth	-	-	-	-	-66.26%	957.75%
Net Cash Per Share	-2.02	-1.70	-1.65	-0.72	0.78	2.70
Filing Date Shares Outstanding	538.65	538.65	538.65	538.65	538.65	540.73
Total Common Shares Outstanding	538.65	538.65	538.65	538.65	543.13	540.73
Working Capital	192.67	137.2	591.84	970.42	951.59	1,482
Book Value Per Share	3.99	4.05	4.61	4.98	5.30	5.56
Tangible Book Value	1,859	1,945	2,244	2,430	2,622	2,759
Tangible Book Value Per Share	3.45	3.61	4.17	4.51	4.83	5.10
Buildings	-	936.67	836.72	712.09	471.86	384.81
Machinery	-	1,641	1,423	1,232	851.39	621.88
Construction In Progress	-	457.86	695.78	736.4	922.19	494.37

Source: S&P Global Market Intelligence. Standard template. Financial Sources.